Two different formulations with equivalent effect? Comparison of serum estradiol suppression with monthly goserelin and trimonthly leuprolide in breast cancer patients

Medical Oncology

Volumn 30, Issue 1, 2013, Pages

  Aydiner, Adnan ^a   Kilic, Leyla ^a   Yildiz, Ibrahim ^a   Keskin, Serkan ^a   Sen, Fatma ^a   Kucucuk, Seden ^a   Karanlik, Hasan ^a   Muslumanoglu, Mahmut ^b   Igci, Abdullah ^b  

^a ISTANBUL UNIVERSITY   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Breast cancer; Estradiol; LHRH agonist; Premenopause

Indexed keywords

ESTRADIOL; FOLLITROPIN; GOSERELIN; LEUPRORELIN; LUTEINIZING HORMONE; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ADULT; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CONTROLLED STUDY; DRUG FORMULATION; ESTRADIOL BLOOD LEVEL; FEMALE; FOLLOW UP; HORMONE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; BLOOD; BREAST TUMOR; CANCER GRADING; CANCER STAGING; COMPARATIVE STUDY; MIDDLE AGED; PATHOLOGY; RADIOIMMUNOASSAY;

ADULT; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; ESTRADIOL; FEMALE; FOLLICLE STIMULATING HORMONE; GOSERELIN; HUMANS; LEUPROLIDE; LUTEINIZING HORMONE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; RADIOIMMUNOASSAY; YOUNG ADULT;

EID: 84880593275     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-012-0354-1     Document Type: Article

References (25)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71-96.
2. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365: 1687-1717.
3. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277-300.
4. Gelber RD, Cole BF, Goldhirsch A, Rose C, Fisher B, Osborne CK, Boccardo F, Gray R, Gordon NH, Bengtsson NO, Sevelda P. Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: meta-analysis of quality adjusted survival. Lancet. 1996;347:1066-71.
5. Conn PM, Crowley W. Gonadotropin-releasing hormone and its analogues. N Engl J Med. 1990;324:93-103.
6. Cockshott ID. Clinical pharmacokinetics of goserelin. Clin Pharmacokinet. 2000;39:27-48.
7. Klijn JG, Blarney RW, Boccardo F, Tominaga T, Duchateau L, Slyvester R. Combined tamoxifen and lutenizing hormone releasing hormone (LHRH) agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. J Clin Oncol. 2001;19:343-53.
8. Jonat W, Kaufmann M, Sauerbrei W, et al. Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer. The Zoladex Early Breast Cancer Research Association Study. J Clin Oncol. 2002;20:4628-35.
9. Boccardo F, Rubagotti A, Amoroso D, et al. Endocrinological and clinical evaluation of two depot formulations of leuprolide acetate in pre- and perimenopausal breast cancer patients. Cancer Chemother Pharmacol. 1999;43:461-6.
10. Dowsett M, Jacobs S, Aherne J, Smith IE. Clinical and endocrine effects of leuproreline acetate in pre- and postmenopausal patients with advanced breast cancer. Clin Ther. 1992;14(Suppl A):97-103.
11. Elston CW, Ellis IO. Pathological prognostic factors in breast cancers. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991;19:403-10.
12. http://www.nccn.org/professionals/physician-gls/pdf/breast.pdf. NCCN guidelines version 1.2012. Breast Cancer. Definition of menopause.
13. Early Breast Cancer Trialists' Cooperative Group. Ovarian ablation in early breast cancer: overview of randomized trials. Lancet. 2005;365:1687-717.
14. Davidson NE, O'Neill AM, Vukov AM, Osborne CK, Martino S, White DR, Abeloff MD. Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188). J Clin Oncol. 2005;23:5973-82.
15. Arriagada R, Le MG, Spielmann M, Mauriac L, Bonneterre J, Namer M, Delozier T, Hill C, Tursz T. Randomized trial of adjuvant ovarian suppression in 926 premenopausal patients with early breast cancer treated with adjuvant chemotherapy. Ann Oncol. 2005;16:389-96.
16. Baum M, Hackshaw A, Houghton J, Rutqvist LE, Fornander T, Nordenskjold B, Nicollucci A, Sainsbury R. Adjuvant goserelin in pre-menopausal patients with early breast cancer patients: results from the ZIPP study. Eur J Cancer. 2006;42:895-904.
17. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011;22:1736-42.
18. Thomas EJ, Jenkins J, Lenton EA, Cooke ID. Endocrine effects of goserelin, a new depot luteinising hormone releasing agonist. Br Med J (Clin Res Ed). 1986;293:1407-8.
19. West CP, Baird DT. Suppression of ovarian activity by Zoladex depot (ICI 118630), a long-acting luteinizing hormone releasing agonist analogue. Clin Endocrinol (Oxf). 1987;26:213-20.
20. Cockshott ID. Clinical pharmacokinetics of goserelin. Clin Pharmacokinet. 2000;39:27-48.
21. Yri OE, Bjoro T, Fossa SD. Failure to achieve castration levels in patients using leuprolide acetate in locally advanced prostate cancer. Eur Urol. 2006;49:54-8.
22. Fujii Y, Yonese J, Kawakami S, Yamamoto S, Okubo Y, Fukui I. Equivalent and sufficient effects of leuprolide acetate and goserelin acetate to suppress serum testosterone levels in patients with prostate cancer. BJU Int. 2008;101:1096-100.
23. Masuda N, Iwata H, Rai Y, Anan K, Takeuchi T, Kohno N, Takei H, Yanagita Y, Noguchi S. Monthly versus 3-monthly goserelin acetate in pre-menopausal patients with estrogen receptor-positive early breast cancer. Breast Cancer Res Treat. 2011;126:443-51.
24. Perachino M, Cavalli V, Bravi F. Testosterone levels in patients with metastatic prostate cancer treated with luteinizing hormone-releasing hormone therapy: prognostic significance? BJU Int. 2009;105:648-51.
25. Dowsett M, Houghton J, Iden C, Salter J, Farndon J, A'Hern R, Sainsbury R, Baurn M. Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status. Ann Oncol. 2006;17:818-26.